The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...

RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients. Background: To date convincing clinical success with oncolytic ...

Rapid 30-minute isatuximab infusions improve patient experiences and reduce healthcare system burdens without compromising safety. FDA-approved isatuximab with VRd shows a 40% risk reduction in ...

In a first-of-its kind study, young children undergoing heart surgery had similar results regardless of whether they received levosimendan intravenously or via inhalation. Pediatric patients who ...

New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed. We conducted a phase 1 clinical trial to ...

Background: Fentanyl, a short-acting synthetic opioid, has a pharmacokinetic profile suited to fast relief of brief episodic pain. Objective: To characterize the pharmacokinetic-pharmacodynamic ...